Clinical Data (CLDA)

[gator16]

7:04AM Clinical Data Licenses Adenosine A2A Agonist to Santen for Development of Ophthalmic Treatments; will receive an upfront payment of $2 million (CLDA) 18.68 : Co and Santen Pharmaceutical announced that Santen has exercised its option to license CLDA's highly selective adenosine A2A agonist compound, ATL313, for the development of topical treatments for certain ophthalmic diseases, including glaucoma. ATL313, a promising late-stage preclinical compound, has shown significant pharmacological effects in vivo and has been nominated as a clinical candidate. Under the license agreement, Clinical Data will receive an upfront payment of $2 million, followed by development, regulatory and commercial milestone payments subject to the fulfillment of certain conditions, as well as royalties on product sales. In exchange, Santen will obtain a worldwide license to adenosine agonist ATL313 and an option for an additional compound for the development and commercialization of treatments for certain ophthalmic diseases, including glaucoma. Clinical Data will retain intellectual property rights for the development of ATL313 outside of the field of any ophthalmic disease, disorder or condition by topical administration into the eye, as well as rights to use the data generated for purposes outside the field. Clinical Data has licensed certain of these rights to CombinatoRx, Inc. for developing B-cell cancer therapies, retaining a co-development option after review of initial Phase IIa study results.